Treatment-related myelodysplasia in patients with primary brain tumors
Open Access
- 29 March 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 14 (5) , 529-540
Abstract
Treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute myelogenous leukemia (t-AML) represent rare secondary events in patients with primary tumors of the nervous system and predominantly affect those treated with alkylating agents or topoisomerase II inhibitors. Temozolomide has become the standard chemotherapeutic agent for malignant gliomas. The emergence of this alkylating agent with little acute toxicity or cumulative myelosuppression has led to off-label protracted chemotherapy for many patients with malignant and even low-grade infiltrative gliomas, raising concern for increased risk of t-MDS/t-AML in the few long-term survivors. On the basis of an extensive literature search, we provide a discussion of epidemiology, pathogenesis, clinical presentation, diagnosis, and therapy of these disorders. t-MDS/t-AML remain rare complications of chemotherapy in patients with primary brain tumors, and the vast majority of patients die of their primary neoplasm. Prospective randomized studies with long-term follow-up are required to accurately assess the risk of t-MDS/t-AML; however, unless survival in the most common gliomas substantially increases, t-MDS/t-AML incidence will likely remain low in this patient population.Keywords
This publication has 46 references indexed in Scilit:
- Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic SyndromesJournal of Clinical Oncology, 2010
- Treatment-related Myelodysplastic Syndrome After Temozolomide Use in a ChildJournal of Pediatric Hematology/Oncology, 2008
- Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: Possible leukemogenic role of temozolomidePediatric Blood & Cancer, 2008
- Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic LeukemiaJAMA, 2007
- Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature1Neuro-Oncology, 2006
- Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer – An updateLeukemia & Lymphoma, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago seriesBlood, 2003
- Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasiaBone Marrow Transplantation, 1997
- Acute leukaemia following malignant ependymoma: A case reportJournal of Surgical Oncology, 1985